Early Stage Non-small Cell Lung Cancer
Conditions
Keywords
early stage non-small cell lung cancer, hypofractionated radiation therapy
Brief summary
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.
Interventions
RADIATIONhypofractionated radiation therapy followed by surgery
hypofractionated radiation therapy followed by surgery
Sponsors
Nationaal Kankerplan
University Hospital, Ghent
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Proof of cT1a/b - 2a/b N0M0 NSCLC * Informed Consent signed * Resectable tumour * Operable patient * \> 18 years old * men and women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pathological effects of hypofractionated radiation therapy | at 2 years | To describe the pathological effects of hypofractionated radioation therapy (RT) and to address the relationship with blood and tissue biomarkers and bio-imaging. |
Secondary
| Measure | Time frame |
|---|---|
| the accuracy of clinical mediastinal staging | from 2 to 5 years |
| the complication rate | from 2 to 5 years |
| local, regional or distant failure | from 2 to 5 years |
| clinical response rate | from 2 to 5 years |
| disease specific overall survival | from 2 to 5 years |
| overall survival | from 2 to 5 years |
| progression free survival | from 2 to 5 years |
Countries
Belgium
Outcome results
None listed